Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, two-arm, 2-stage, Phase 2 study of NKTR-102 in patients
with metastatic or locally advanced platinum-resistant ovarian cancer.
Approximately 70 patients will be randomized 1:1 into one of two treatment arms. NKTR-102
will be administered at a dose level of 145 mg/m^2 in both arms. In Arm A, NKTR-102 will be
given on a q14d schedule. In Arm B, NKTR-102 will be given on a q21d schedule. After the
initial 70 patients have been enrolled, Arm B will enroll approximately 110 additional
patients.